scholarly journals Novel Genetic Variants Associated with Death Due to Acute Lymphoblastic Leukemia Within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

2017 ◽  
Vol 23 (3) ◽  
pp. S18 ◽  
Author(s):  
Theresa E. Hahn ◽  
Leah Preus ◽  
Philip L. McCarthy ◽  
Marcelo C. Pasquini ◽  
Kenan Onel ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Genetic Variants ◽  
Marrow Transplantation ◽  
Lymphoblastic Leukemia ◽  
Unrelated Donor ◽  
Donor Blood ◽  
Matched Unrelated Donor ◽  
Blood And Marrow Transplantation ◽  
One Year

scholarly journals Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation

Blood ◽  
2018 ◽  
Vol 131 (22) ◽  
pp. 2490-2499 ◽  
Author(s):  
Qianqian Zhu ◽  
Li Yan ◽  
Qian Liu ◽  
Chi Zhang ◽  
Lei Wei ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Germ Line ◽  
Survival Outcomes ◽  
Unrelated Donor ◽  
Donor Blood ◽  
Matched Unrelated Donor ◽  
Blood And Marrow Transplantation ◽  
Key Points ◽  
Variant Genotype ◽  
Exome Chip

Key Points We conducted the first exome-wide association study between germ line variant genotype and survival outcomes after unrelated-donor BMT. A number of novel genes were found to significantly affect survival outcomes.

Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission

Blood ◽  
2002 ◽  
Vol 99 (9) ◽  
pp. 3151-3157 ◽  
Author(s):  
Nancy Bunin ◽  
Michael Carston ◽  
Donna Wall ◽  
Roberta Adams ◽  
James Casper ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Lymphoblastic Leukemia ◽  
Marrow Transplantation ◽  
Lymphoblastic Leukemia ◽  
Allogeneic Bone Marrow Transplantation ◽  
Unrelated Donor ◽  
Allogeneic Bone ◽  
Hla Matching ◽  
First Remission ◽  
Related Donor

Abstract Allogeneic bone marrow transplantation (BMT) may be curative for more patients than chemotherapy for the child with relapsed acute lymphoblastic leukemia. This study reviewed the outcomes of 363 children with acute lymphoblastic leukemia in second remission who received unrelated donor BMT from 1988 to 2000 in order to define prognostic factors that affect leukemia-free survival (LFS). Median patient age was 9 years (range, 0-19 years), and median follow-up 29 was months (range, 0-125 months). The median duration of first remission was 24 months (range, 0-109 months). Prognostic factors, including age, duration of first remission, HLA matching, and graft-versus-host (GVH) disease, were analyzed using both univariate and multivariate analyses. Overall survival was 38%, and LFS was 36% at 5 years. LFS was significantly worse for patients 15 years or older (log-rank, P = .009). HLA matching was associated with improved LFS. Acute GVH disease developed in 71%, with 29% having grades III-IV. The incidence of chronic GVH disease was 39% for patients who survived more than 80 days and was significantly higher for female patients receiving marrow from female donors (P = .0009). Transplantation-related mortality was 42% and was associated with HLA mismatches, age 15 years and older, and first remission less than 12 months. The 5-year estimate for relapse was 22%, with first remission at least 6 months associated with a lower risk. Results of unrelated donor BMT appear similar to multi-institutional studies of matched related donor BMT, and this approach appears to be curative for many patients. However, innovative approaches are needed for patients with initial remissions of less than 6 months and for older teenagers.

scholarly journals HSCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

JBMTCT ◽  
2021 ◽  
Vol 4 (1) ◽  
pp. 61-71
Author(s):  
Sociedade Brasileira de TMO SBTMO ◽  
Marco Aurelio Salvino ◽  
Maura Valerio Ikoma ◽  
Rodolfo Soares ◽  
Andreza Ribeiro ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Marrow Transplantation ◽  
Lymphoblastic Leukemia ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplantation ◽  
Brazilian Society

THE BRAZILIAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (SBTMO) PRESENTS THE BRAZILIAN GUIDELINES ON HEMATOPOIETIC STEM CELL TRANSPLANTATION

scholarly journals Autologous Versus Unrelated Donor Allogeneic Marrow Transplantation for Acute Lymphoblastic Leukemia

Blood ◽  
1997 ◽  
Vol 90 (8) ◽  
pp. 2962-2968 ◽  
Author(s):  
Daniel J. Weisdorf ◽  
Amy L. Billett ◽  
Peter Hannan ◽  
Jerome Ritz ◽  
Stephen E. Sallan ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Marrow Transplantation ◽  
Clinical Decision Making ◽  
Lymphoblastic Leukemia ◽  
Disease Free Survival ◽  
Clinical Decision ◽  
Unrelated Donor ◽  
University Of Minnesota ◽  
Allogeneic Marrow Transplantation ◽  
Related Donor

Abstract Bone marrow transplantation (BMT) can cure patients with high-risk or recurrent acute lymphoblastic leukemia (ALL). Those lacking a related donor can receive either autologous or histocompatible unrelated donor (URD) marrow. Autotransplantation may result in higher risk of relapse, whereas URD allografts, although associated with serious posttransplant toxicities, may reduce relapse risk. Six years (1987 to 1993) of consecutive autologous BMT (University of Minnesota, Dana Farber Cancer Institute; n = 214) were compared with URD transplants (National Marrow Donor Program; n = 337). Most transplants (70% autologous, 48% URD) were in early remission (first or second complete remission [CR1 or CR2]); 376 patients (75% autologous, 64% URD) were less than 18 years old. Autologous BMT led to significantly lower transplant-related mortality (TRM; relative risk [RR] 0.35; P = .001). URD transplantation offered greater protection against relapse (autologous RR 3.1; P = .001). Patients greater than 18 years old, women, and BMT recipients beyond CR2 had higher TRM, whereas adults, BMT recipients in CR2+, or BMT recipients during 1991 through 1993 had significantly more relapse. After 25 months median follow-up, 100 URD and 56 autologous recipients survive leukemia free. URD BMT in CR2 resulted in superior disease-free survival (DFS), especially for adult patients. Multivariate analysis showed superior DFS for children, men, and BMT during CR1 or 2. Autologous and URD BMT can extend survival for a minority of patients unlikely to be cured by chemotherapy, and the results with either technique are comparable. Greater toxicity and TRM after URD BMT are counterbalanced by better protection against relapse. Prospective studies addressing additional clinical variables are needed to guide clinical decision making about transplant choices for patients with ALL.

Sign in / Sign up

Export Citation Format

Share Document